Efficacy

Introduction to Qulipta (Atogepant) for Migraine

Qulipta (atogepant) is a medication specifically approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of episodic migraine in adults. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists. CGRP is a molecule involved in migraine attacks, and by blocking its receptor, atogepant helps to reduce the frequency of migraine days. Clinical trials have demonstrated the efficacy of Qulipta in reducing the monthly average number of migraine days when taken regularly as a preventive treatment.

Efficacy of Qulipta (Atogepant) in Clinical Trials

The efficacy of Qulipta was evaluated in a pivotal phase 3 trial, where it significantly reduced the mean number of migraine days per month compared to placebo. Patients treated with atogepant experienced a decrease in the number of migraine days, with some patients reporting at least a 50% reduction in their monthly migraine days. The treatment effect was observed as early as the first month and was sustained throughout the 12-week treatment period. Additionally, Qulipta was associated with improvements in other measures such as physical functioning and quality of life.

Introduction to Zavzpret (Zavegepant) for Migraine

Zavzpret (zavegepant) is another CGRP receptor antagonist, but unlike Qulipta, it is developed for the acute treatment of migraine with or without aura in adults. As an acute treatment, zavegepant is intended to be used at the onset of migraine symptoms to alleviate pain and other associated symptoms of a migraine attack. The efficacy of Zavzpret has been supported by clinical trials that showed its ability to provide pain relief and address the most bothersome symptoms of a migraine episode for many patients.

Efficacy of Zavzpret (Zavegepant) in Clinical Trials

In clinical studies, Zavzpret demonstrated a statistically significant difference from placebo in the proportion of patients achieving pain freedom and freedom from their most bothersome symptom (such as nausea, sensitivity to light, or sensitivity to sound) two hours after dosing. The benefits of zavegepant were observed as early as 15 minutes for some patients, with a durable effect up to 48 hours post-dose for others. This rapid onset of action and sustained relief make Zavzpret an important option for the acute management of migraine attacks.